New A.I. Enabled Genome Imaging Revolutionizes Cancer Classification

The future of genomics is here, driven by the transformative power of A.I.

This advancement has resulted in a paradigm shift in which medicine has become personalized and predictive, especially in terminal conditions such as cancer.

“Genomic Stocks Are in The First Inning of a Multi-Year Megatrend”
~ Olivier Garrett, Forbes Contributorⁱ

Before Frederick Sanger introduced a new understanding of DNA to the world in 1977, few people had heard of genome sequencing, aptly named Sanger sequencing.

Those that did, knew it only as a means of understanding the complex patterns that make up the body’s genetic code.

They didn’t know it could act as a powerful tool for locating errors in the genetic code, that eventually lead to a variety of diseases and disorders.

We know that now. Genome sequencing has the potential to identify all sorts of intractable problems — from cancers like Myeloma, to neurological disorders like Huntington’s disease.

The relatively recent medical field could very easily wind up the largest advance of all time.

And that success has paid off handsomely for early investors. Specialized players like Illumina, Inc. did famously well, shooting up more than 10X in the early days of deployment.

But sequencing was only our first step into the world of genetic medicine. There are much more powerful developments on the horizon.

And one of them has now arrived.

Just as with Sanger sequencing, few people have heard of telomeres.

Those that have only know them as ‘caps’ at the end of chromosomes. They’ve often been compared to the plastic caps at the end of the shoelaces that prevent the laces from unraveling.

Telomeres help keep our core genetic material protected and unaffected by environmental damage.

And, it turns out, telomere failures are often responsible for the growth of various types of cancers — including blood cancers like Multiple Myeloma.

Combining advanced cell selection and analysis techniques, a new A.I. software that can analyze millions of pieces of data a second, and a new way of viewing 3D images of telomeres called TeloView…

We now can characterize some cancers before they become lethal… profile potential treatment plans against individual genetic markers… and efficiently design a personalized treatment course to combat the cancer.

Is it a cure for cancer? Not quite yet.

But thanks to the rapid advances in this field of genetics, a cure might be just around the corner.

And companies like Telo Genomics (TSX-V: TELO) (OTCQB: TDSGF) are leading the charge.

Cancer Is on the Rise - Straining Medical Systems, and Sending Health Care Costs Soaring

Cancer. It’s one of the most prevalent diseases in the world today.

According to the National Cancer Institute, almost 40% of the global population will be diagnosed with cancer at some point during their lifetime.

Globally, the number of individuals under the age of 50 diagnosed with cancer has risen by nearly 80% in three decades, according to BMJ Oncology, in what was widely considered the largest study of its kind.ii

The American Cancer Society (ACS) estimates that roughly 1.8 million new cases of cancer will be diagnosed in the U.S. in 2023 and that more than 16.9 million Americans living today have a cancer history.

It’s also one of the leading causes of death worldwide… accounting for nearly 10 million deaths in 2020, or almost 1 out of every 6 deaths.¹

As a leading cause of death and disease in the U.S., not only does cancer take an enormous toll on the health of patients and survivors—it also has a tremendous financial impact.ⁱⁱ

Over the next 30 years, cancer is expected to cost the world 25.2 trillion dollars² – in health care costs, lost labor, and lost savings.

As a result, controlling the cost of health care is quickly becoming a national concern. In 2021, the U.S. spent $4.1 trillion on health care.^iv $200 Billion of that was allocated to cancer. This amount is only expected to rise as the population ages, and new, more expensive, treatments are adopted. The need for more intelligent disease screening, and a customized approach to treatment, has never been greater.

Predictive, Personalized Medicine: The Future of Healthcare

Cancer is a conundrum, operating differently in every instance.

From person, to type of cancer, to location in the body, and even environment – these factors play into the way in which cancer will behave in the body.

Some grow fast and spread quickly…

While others grow so slowly (or even not at all) that they can evade diagnosis or even treatment for years.

It’s easy to see the copious advantages of the medical landscape evolving towards a more personalized approach to diagnosis and treatment.

Especially when one considers the practice of medicine has historically been reactive. Even today, we are forced to wait until the onset of disease to treat or cure it.

The potential for a genome-based medical approach, is to shift the emphasis in medicine from reaction to early detection and personalized intervention.

It comes with many benefits, including allowing doctors to prescribe more effective drugs, avoid drugs with unnecessary side effects, and limit the risk of overtreatment, which has become a growing issue in the treatment of cancer.

In fact, it has been suggested that up to 30% of cancer treatments are unnecessary, costing medical systems hundreds of billions a year in treatment.^v

According to a Danish study published in Annals of Internal Medicine, one in three women with breast cancer detected by a mammogram is treated unnecessarily.

The study raises the uncomfortable possibility that some women who believe their lives were saved by mammograms were actually harmed by cancer screenings that led to surgery, radiation and even chemotherapy that they didn’t need, said Dr. Otis Brawley, chief medical officer of the American Cancer Society.vi

Subjecting a patient to treatment unnecessarily is both costly and can subject the patient to residual harm caused by radiation therapy, chemotherapy, or strong drugs.

The Advent of Genome-Based Cancer Prognosis and Treatment

Rather than a one size fits all approach, the TeloView platform allows for a personalized approach to cancer diagnosis and treatment.

It can empower physicians with a diagnostic tool that allows for close monitoring of a patient’s disease progress. It can also more accurately determine their risk and at what stage treatment may be required.

That means they can make more informed treatment decisions – sparing unnecessary treatments, their associated costs and side effects – and focusing on the most effective solutions.

It does this using a proprietary 3-D analysis of the telomeres from an individual patient.

Now remember, it is these telomeres that are key, as they act as protective end caps for chromosomes.

Just recently, we’ve started to understand the role that telomeres play in overall health, and for the development of a variety of different diseases.

Most notably, a type of blood-borne cancer, called Multiple Myeloma.

You see, progressive shortening of telomeres leads to growth arrest and cell death in normal cells.

But a serious issue, called “telomere dysfunction” is commonly seen in cancer cells where critically short telomeres do not trigger cell death.

This telomere dysfunction is characterized by an altered organization of the telomeres, often associated with aggregates, as well as altered numbers and lengths of individual telomeres.

When the resultant disease is discovered early and the patient has limited symptoms, it’s called Smouldering Multiple Myeloma (SMM).

Current diagnosis for SMM is a blood test followed by one of two invasive procedures, bone marrow aspiration or bone marrow biopsy. Both involve inserting large, long needles into the bone and drawing samples of the bone marrow – a highly invasive test – and one that medical professionals and patients would prefer to administer minimally.

In the US alone, prognostic testing and monitoring of SMM is estimated to be up to 500,000 tests per year, coming in at a nearly $1 billion market value.

Now on its own, SMM is not always a cause for major concern. It is only if, and when, SMM progresses to the stage of Multiple Myeloma that treatment becomes necessary.

In the case of multiple myeloma, cancerous plasma cells build up in bone marrow. In the bone marrow, the cancer cells crowd out healthy blood cells. Rather than make helpful antibodies, the cancer cells make proteins that don’t work correctly.^vii

The result is a debilitating disease that ranges between $126,000 to $256,000 per year to treat. ^viii

That means it is up to medical professionals to decide if a patient with SMM is at high risk to develop Multiple Myeloma, and whether to prescribe treatment.

It becomes clear how vital that information is, when one considers that only 50% of patients with SMM will develop Multiple Myeloma within 5 years. ^ix

That’s why, until now the standard of care for patients that have been diagnosed with SMM has been to monitor. But there is a movement toward treating patients identified in the high-risk category to delay the onset of active multiple myeloma and its debilitating symptoms.

However, this therapeutic approach has been limited by the lack of a reliable, non-invasive prognostic test for high-risk SMM.

That’s Where Telo Genomics (TSX-V: TELO) (OTCQB: TDSGF) Comes In

The TeloView platform can provide medical professionals with a better, predictive diagnosis of who requires treatment and who does not.

Using artificial intelligence, this 3-D modelling software analyses data and offers important actionable information. That includes the disease’s stage of progression, as well as how it will, or is responding to therapy.

And it’s done via a non-invasive blood test– which means it can be used repeatedly for monitoring the progression of the disease, and the effectiveness of, or requirement for treatment.

At the International Myeloma Society annual meeting, Telo Genomics presented positive results in assessing Multiple Myeloma.

Initial data demonstrated repeatable sensitivity three-fold higher than what is currently being used in clinical practice.

It’s a capability never made available to the medical community before, with the potential to revolutionize disease monitoring and treatment.

And Telo Genomics is finally getting the recognition they deserve. These results are expected to be published in the journal of Clinical Lymphoma, Myeloma & Leukemia in the near-term.

Telo Genomics Is Poised to Change the Diagnostic Landscape Forever

The company has done extensive testing with the Mayo Clinic
The company has conducted over 25 clinical studies…
Published over 140 peer reviewed papers…
Has evaluated over 3,000 patients for multiple varieties of cancer as well as Alzheimer’s disease…
And has filed 18 patents across Canada, USA, and Europe.
Plus, the company has developed strong clinical relationships, that include Harvard University, Dana-Farber Cancer Institute, The Mayo Clinic, The Oncology Institute of Hope & Innovation, and IMBCR.

In addition, the company currently has not one, but 14 potential diseases their technology can address, that are in the pipeline for further development.

Telo Genomics holds a portfolio of patents related to three-dimensional telomere analysis for proliferative diseases, including, but not limited to… ^x

Haematological disorders such as Hodgkin’s lymphoma (A $8.3 billion market)^xi
Chronic myeloid leukaemia (A $7.2 Billion market)^xii
Prostate cancer (A $12 billion market)^xiii
Breast cancer (A $28.8 billion market)^xiv
Lung cancer (A $29.5 billion market)^xv
Melanoma (A $5.8 billion market)^xvi
and Alzheimer disease (A $6.1 billion market).

That’s a combined addressable market size of nearly $100 billion.

The best part is, Telo Genomics is ready for commercial launch and the monetization of its technology.

Commercial Launch Is Underway

After nearly 10 years of research, dozens of clinical studies, and thousands of patient studies, it’s time for Telo Genomics Corp. (TSX-V: TELO) (OTCQB: TDSGF) to commercialize and monetize their proven technology.

By the end of 2023, its state-of-the-art Canadian based laboratory will be working with hospitals, doctors, and a range of medical professionals across North America, providing them with their proprietary lab results testing for SMM.

“The commercial launch of our flagship TeloView platform is a major milestone for our Company” stated Telo Genomics’ CEO Kris Weinberg.

“The commercial launch of our flagship TeloView platform is a major milestone for our Company” stated Telo Genomics’ CEO Kris Weinberg. “I am extremely proud of our entire team who have put forth a tremendous effort over many years in the development of our platform. Our presentations at this year’s International Myeloma Society (“IMS”) annual meeting and the American Society of Clinical Oncology’s annual meeting were received very positively and have generated many leads for our new assay. We are also very active in discussions with platform partners and in the development of new tests in additional applications.”

The medical profession has long waited a cost effective, accurate, non-invasive test for this disease, that can be easily administered multiple times per year.

Now Telo Genomics is rolling out to fill that void… And right at the perfect time.

The Entire Genomics Industry Has Been on Fire

Most important for investors, the market cap of other genomics companies are in the hundreds of millions…

Illumina (ILMN)—the worldwide leader in genetic sequencing—has surged more than 188% since 2017.
CRISPR Therapeutics (CRSP)—a gene editing pioneer—surged more than 400% in its first two years after its IPO.
Editas Medicine (EDIT)—another major player in the gene editing space—spiked 131% in its first two months as a publicly traded company.
NeoGenomics (NEO), which specializes in cancer diagnostics, has rallied more than 5,000% since 2016.

In contrast, Telo Genomics (TSX-V: TELO) (OTCQB: TDSGF) is currently sitting at market cap of only approximately $11 million…

Meanwhile, they’re developing some of the most advanced genomic diagnostic tools.

That means early investors can acquire significant share positions at very low costs.

A CEO and Scientific Advisory With Unparalleled Experience

Kris Weinberg, CEO

Mr. Weinberg is an experienced commercial executive in the field of cancer molecular diagnostics and recognized leader in the disciplines of commercial infrastructure build-out, third party reimbursement and assay pipeline management.

He has managed successful development efforts at numerous early-stage companies across multiple platforms and cancer disease types. Mr. Weinberg launched the GEM ExTra™ Cancer Panel for Ashion Analytics, a TGen® Clinical Lab. Based on this successful market introduction, Ashion was acquired by Exact Sciences (NASDAQ: EXAS) in February of 2021 for approximately 110 million dollars.^xvii

In prior early-commercial leadership roles at Natera (NSDQ: NTRA), Guardant Health (NADQ: GH) current market cap 1.5 billion, Biodesix (NSDQ:BDSX) current market cap 167 million and Genomic Health ( NADQ: GHI – EXAS) current market cap 11.3 billion.

Mr. Weinberg is a US Army veteran, cancer survivor, and has served on the Board of Directors for the Lymphoma Research Foundation [LRF].

Dr. Sabine Mai, Founder, Director and Chair of the Clinical and Scientific Advisory Board

Dr. Mai is Canada Research Chair (Tier 1) in Genomic Instability and Nuclear Architecture of Cancer, Professor of Physiology and Pathophysiology, Biochemistry and Medical Genetics, Human Anatomy and Cell Science, University of Manitoba. Director of The Genomic Centre for Cancer Research and Diagnosis (GCCRD) at the University of Manitoba. She is also Director of The Genomic Centre for Cancer Research and Diagnosis (GCCRD) at the University of Manitoba.

6 Reasons to Consider Telo Genomics Corp. (TSX-V: TELO) (OTCQB: TDSGF)

Full Commercial Launch by the end of 2023 – The company recently received its ISO 15189 accreditation certifying Telo Genomics to offer its TeloView tests as laboratory developed tests (LDTs) for clinical use from its central laboratory in Toronto.
Globally Scalable Diagnostic Tool – Every country in the world is facing rising health care cost and have a desire to lower them. Having a diagnostic tool like TeloView can assist in lowering the amount of unnecessary medical treatments and costs for individual patients. Telo Genomics can licence their patented TeloView technology globally.
Experienced Management – Kris Weinberg is an experienced commercial executive in the field of cancer molecular diagnostics and recognized leader in the disciplines of commercial infrastructure build-out, third party reimbursement and assay pipeline management.
Low Comparative Valuation – Telo Genomics pre commercial launch valuation is only $11.7 million, compared to NeoGenomics (NEO), which specializes in cancer diagnostics whose market cap is $1.59 Billion.
Strong Industry Acceptance and Reviews – Over 140 peer reviewed papers, 25 clinical studies, extensive testing with the Mayo Clinic. Telo Genomics presented at both the International Myeloma Society (“IMS”) annual meeting and the American Society of Clinical Oncology’s annual meeting. Both presentations were received very positively.
Revolutionary Patented Technology – Telo Genomics has secured intellectual property protection in many jurisdictions around the world. The scope of the IP covers its core technology and specific applications of the technology. The longevity of Telo Genomic’s intellectual property protection varies from country to country but spans up to year 2034.The company has filed 18 patents across Canada, USA, and Europe to protect its intellectual properties.

On top of a heavy societal toll, the global economic cost of cancer is estimated to exceed $25 trillion over 30 years.^xviii Telo Genomics offers a unique solution that allows for better identification, monitoring, and treatment options for this prevalent disease.

And now with the commercial launch of the company’s flagship TeloView platform, we expect to see this small company garner quick attention and enthusiasm from the biotech sector.

For more information about Telo Genomics (TSX-V: TELO) (OTCQB: TDSGF) visit the company’s website or download its free investor presentation by entering your email address below.

Learn More About Telo Genomics (TSX-V: TELO) (OTCQB: TDSGF) at your brokerage today!

¹https://www.who.int/news-room/fact-sheets/detail/cancer
² https://www.advisory.com/daily-briefing/2023/03/09/cancer-costs
ⁱ https://www.forbes.com/sites/oliviergarret/2020/05/14/genomic-stocks-are-in-the-first-inning-of-a-multi-year-megatrend/
ⁱⁱ https://www.theguardian.com/society/2023/sep/05/cancer-cases-in-under-50s-worldwide-up-nearly-80-in-three-decades-study-finds#:~:text=Global%20cases%20of%20early%20onset,or%20younger%20grew%20by%2027%25.
ⁱⁱⁱ https://www.fightcancer.org/sites/default/files/National%20Documents/Costs-of-Cancer-2020-10222020.pdf
^iv https://healthadministrationdegree.usc.edu/blog/most-expensive-disease-to-treat-infographic/
^v https://news.cancerresearchuk.org/2018/03/06/overdiagnosis-when-finding-cancer-can-do-more-harm-than-good/
^vi https://edition.cnn.com/2017/01/10/health/breast-cancer-unnecessary-treatment-study-partner/index.html
^vii https://www.mayoclinic.org/diseases-conditions/multiple-myeloma/symptoms-causes/syc-20353378
^viii https://www.webmd.com/cancer/multiple-myeloma/multiple-myeloma-financial-costs
^ix https://www.cancer.gov/news-events/cancer-currents-blog/2019/lenalidomide-slows-progression-smoldering-myeloma
^x https://www.sedarplus.ca/csa-party/viewInstance/view.html?id=0c11f8b7998bcd9673f92360c0c2968c4191927aef24d078&_timestamp=10761413697914556
^xi https://www.maximizemarketresearch.com/market-report/hodgkin-lymphoma-treatment-market/124690/
^xii https://www.coherentmarketinsights.com/market-insight/chronic-myeloid-leukemia-treatment-market-1726#:~:text=The%20global%20chronic%20myeloid%20leukemia,period%20(2021%2D2028)
^xiii https://www.precedenceresearch.com/prostate-cancer-market#:~:text=The%20global%20prostate%20cancer%20market,period%20from%202023%20to%202032.
^xiv https://www.precedenceresearch.com/breast-cancer-market#:~:text=The%20global%20breast%20cancer%20market,segments%20involved%20the%20largest%20market.
^xv https://www.gminsights.com/industry-analysis/lung-cancer-market#:~:text=Industry%20Statistics,raise%20awareness%20about%20the%20disease.
^xvi https://www.stratviewresearch.com/1643/melanoma-therapeutics-market.html#:~:text=The%20melanoma%20therapeutics%20market%20was,USD%2011.05%20billion%20in%202028.
^xvii https://www.marketscreener.com/quote/stock/EXACT-SCIENCES-CORPORATIO-9232/news/Exact-Sciences-Corporation-completed-the-acquisition-of-Ashion-Analytics-LLC-from-PMed-Management-33441566/
^xviii https://www.healio.com/news/hematology-oncology/20230223/global-economic-cost-of-cancer-estimated-to-exceed-25-trillion-over-30-years

IMPORTANT NOTICE AND DISCLAIMER

This article is a paid advertisement. Think Ink Marketing and its owners, managers, employees, and assigns (collectively “the Publisher”) is often paid by profiled companies or third parties to organize marketing campaigns, which include the creation and dissemination of these types of communications. In this case, in an effort to enhance public awareness of Telo Genomics (“TELO”) and its securities, TELO has provided the Publisher with a budget of approximately $10,000.00 USD to cover the costs associated with the creation and distribution of this communication. The Publisher may retain any excess sums after expenses as its compensation. This compensation should be viewed as a major conflict with our ability to be unbiased. Readers should beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you receive this communication, which has the potential to hurt share prices. Frequently companies profiled in our articles experience a large increase in volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases. The investor awareness marketing may be as brief as one day, after which a large decrease in volume and share price may likely occur. This communication is not, and should not be construed to be, an offer to sell or a solicitation of an offer to buy any security. Neither this communication nor the Publisher purport to provide a complete analysis of any company or its financial position. The Publisher is not, and does not purport to be, a broker-dealer or registered investment adviser. This communication is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the company. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the advertised company’s SEC, SEDAR and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk. Past performance does not guarantee future results. This communication is based on information generally available to the public and on interviews with company management, and does not (to the Publisher’s knowledge, as confirmed by TELO) contain any material, non-public information. The information on which it is based is believed to be reliable. Nevertheless, the Publisher cannot guarantee the accuracy or completeness of the information.

SHARE OWNERSHIP.

The Publisher does not own any shares of TELO and has no information concerning share ownership by others of in TELO. The Publisher cautions readers to beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you read the articles on this website and this has the potential to hurt share prices. Frequently companies profiled in such articles experience a large increase in volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases.

FORWARD LOOKING STATEMENTS.

This publication contains forward-looking statements, including statements regarding expected continual growth of the featured companies and/or industry. The Publisher notes that statements contained herein that look forward in time, which include everything other than historical information, involve risks and uncertainties that may affect the companies’ actual results of operations. Wherever possible, words such as “predicts”, “projects”, “targets”, “plans”, “expects”, “does not expect”, “budget”, “scheduled”, “estimates”, “forecasts”, “anticipate” or “does not anticipate”, “believe”, “intend” and similar expressions or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved, or the negative or grammatical variation thereof or other variations thereof, or comparable terminology have been used to identify forward-looking statements. These forward-looking statements include, among other things, statements relating to: (a) revenue generating potential with respect to TELO’s industry; (b) market opportunity; (c) TELO’s business plans and strategies; (d) services that TELO intends to offer; (e) TELO’s milestone projections and targets; (f) TELO’s expectations regarding receipt of approval for regulatory applications; (g) TELO’s intentions to expand into other jurisdictions including the timeline expectations relating to those expansion plans; and (h) TELO’s expectations regarding its ability to deliver shareholder value. Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, as of the date of this document including, without limitation, assumptions about: (a) the ability to raise any necessary additional capital on reasonable terms to execute TELO’s business plan; (b) that general business and economic conditions will not change in a material adverse manner; (c) TELO’s ability to procure equipment and operating supplies in sufficient quantities and on a timely basis; (d) TELO’s ability to enter into contractual arrangements; (e) the accuracy of budgeted costs and expenditures; (f) TELO’s ability to attract and retain skilled personnel; (g) political and regulatory stability; (h) the receipt of governmental, regulatory and third-party approvals, licenses and permits on favorable terms; (i) changes in applicable legislation; (j) stability in financial and capital markets; and (k) expectations regarding the level of disruption as a result of COVID-19. Such forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of TELO to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation: (a) TELO operations could be adversely affected by possible future government legislation, policies and controls or by changes in applicable laws and regulations; (b) public health crises such as the COVID-19 pandemic may adversely impact TELO’s business; (c) the volatility of global capital markets; (d) political instability and changes to the regulations governing TELO’s business operations (e) TELO may be unable to implement its growth strategy; and (f) increased competition. Except as required by law, the Website Host undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future event or otherwise.

INDEMNIFICATION/RELEASE OF LIABILITY.

By reading this communication, you acknowledge that you have read and understand this disclaimer, and further that to the greatest extent permitted under law, you release the Publisher, its affiliates, assigns and successors from any and all liability, damages, and injury from this communication. You further warrant that you are solely responsible for any financial outcome that may come from your investment decisions.

INTELLECTUAL PROPERTY.

Think Ink Marketing is the Publisher’s trademark. All other trademarks used in this communication are the property of their respective trademark holders. The Publisher is not affiliated, connected, or associated with, and is not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made by the Publisher to any rights in any third-party trademarks.

IMPORTANT NOTICE AND DISCLAIMER

This website is owned and hosted by Market Tactic Media Ltd. Articles appearing on this website should be considered paid advertisements. Market Tactic Media Ltd. and its owners, managers, employees, and assigns (collectively “the Website Host”) is often paid by marketing companies to host websites on which articles profiling public companies are published. The Website Host has not been compensated by any of the profiled companies. The Website Host’s compensation for articles appearing on this website is as follows:

The Website Host has been paid approximately $500 per week while the advertisement campaign is active by Think Ink Marketing as compensation to host the article profiling Telo Genomics (“TELO”).

SHARE OWNERSHIP

The Website Host does not own any shares of any profiled compannies and has no information concerning share ownership by others of any profiled companies. The Website Host cautions readers to beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you read the articles on this website and this has the potential to hurt share prices. Frequently companies profiled in such articles experience a large increase in volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases.

NO SECURITIES OFFERED

The articles on this website are not, and should not be construed to be, offers to sell or solicitations of an offer to buy any security. Neither the articles on this website nor the Website Host purport to provide a complete analysis of TELO or its financial position. The Website Host is not, and does not purport to be, a broker-dealer or registered investment adviser. The articles on this website are not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about TELO Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in TELO’s SEC, SEDAR and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk.

INDEMNIFICATION/RELEASE OF LIABILITY

By reading articles on this website, you acknowledge that you have read and understood this disclaimer, and further that to the greatest extent permitted under law, you release the Website Host, its affiliates, assigns and successors from any and all liability, damages, and injury from articles appearing on this website. You further warrant that you are solely responsible for any financial outcome that may come from your investment decisions.

LINKS TO THIRD PARTY WEBSITES

This website enables users to link to external websites not under the control of The Website Host. The Website Host has no control over the nature, content, and availability of those sites. The inclusion of any links is not intended as, and should not be construed as, a recommendation or endorsement of the content or views expressed on such external websites. The Website Host expressly disclaims any representation concerning the quality, safety, suitability, or reliability of any external websites and the content and materials contained in them. It is important for users to take necessary precautions, especially to ensure appropriate safety.

INTELLECTUAL PROPERTY

The Market Tactic is the Website Host’s trademark. All other trademarks used in this communication are the property of their respective trademark holders. The Website Host is not affiliated, connected, or associated with, and is not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made by the Website Host to any rights in any third-party trademarks.

FORWARD LOOKING INFORMATION

This document contains forward-looking information and forward-looking statements, within the meaning of applicable Canadian securities legislation, (collectively, “forward-looking statements”), which reflect expectations regarding TELO’s future growth, future business plans and opportunities, expected activities, and other statements about future events, results or performance. Wherever possible, words such as “predicts”, “projects”, “targets”, “plans”, “expects”, “does not expect”, “budget”, “scheduled”, “estimates”, “forecasts”, “anticipate” or “does not anticipate”, “believe”, “intend” and similar expressions or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved, or the negative or grammatical variation thereof or other variations thereof, or comparable terminology have been used to identify forward-looking statements. These forward-looking statements include, among other things, statements relating to: (a) revenue generating potential with respect to TELO’s industry; (b) market opportunity; (c) TELO’s business plans and strategies; (d) services that TELO intends to offer; (e) TELO’s milestone projections and targets; (f) TELO’s expectations regarding receipt of approval for regulatory applications; (g) TELO’s intentions to expand into other jurisdictions including the timeline expectations relating to those expansion plans; and (h) TELO’s expectations regarding its ability to deliver shareholder value. Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, as of the date of this document including, without limitation, assumptions about: (a) the ability to raise any necessary additional capital on reasonable terms to execute TELO’s business plan; (b) that general business and economic conditions will not change in a material adverse manner; (c) TELO’s ability to procure equipment and operating supplies in sufficient quantities and on a timely basis; (d) TELO’s ability to enter into contractual arrangements; (e) the accuracy of budgeted costs and expenditures; (f) TELO’s ability to attract and retain skilled personnel; (g) political and regulatory stability; (h) the receipt of governmental, regulatory and third-party approvals, licenses and permits on favorable terms; (i) changes in applicable legislation; (j) stability in financial and capital markets; and (k) expectations regarding the level of disruption as a result of COVID-19. Such forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of TELO to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation: (a) TELO’s operations could be adversely affected by possible future government legislation, policies and controls or by changes in applicable laws and regulations; (b) public health crises such as the COVID-19 pandemic may adversely impact TELO’s business; (c) the volatility of global capital markets; (d) political instability and changes to the regulations governing TELO’s business operations (e) TELO may be unable to implement its growth strategy; and (f) increased competition. Except as required by law, the Website Host undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future event or otherwise.

HISTORICAL INFORMATION

Any graphs, tables or other information demonstrating the historical performance or current or historical attributes of TELO or any other entity contained in this document are intended only to illustrate historical performance or current or historical attributes of TELO or such entities and are not necessarily indicative of future performance of TELO or such entities.

STOCK INFORMATION

Sector: Biotech

TSX-V:TELO, OTCQB:TDSGF

RELATED NEWS

Get Telo Investor Alerts